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1-Year Results of the Randomized AIDA STEMI TrialTo the Editor: In patients with ST-segment elevation myocardial
infarction (STEMI), direct intracoronary as compared with stan-
dard intravenous bolus administration of the glycoprotein IIb/IIIa
receptor antagonist abciximab acutely causes higher local drug
concentrations, greater glycoprotein IIb/IIIa receptor occupancy,
and enhanced inhibition of platelet aggregation at the site of
thrombus and downstream within the coronary capillary bed (1).
These effects might exert a protective effect on the myocardial
microcirculation at the time of reperfusion.
At short-term follow-up (90 days), the largest randomized trial to
date (AIDA STEMI [Abciximab Intracoronary Versus Intrave-
nously Drug Application in STEMI]) comparing intracoronary and
intravenous abciximab bolus application in patients with STEMI
undergoing primary percutaneous coronary intervention (PCI) could
not show a signiﬁcant difference in a compositemajor adverse cardiac
events endpoint, mortality, reinfarction, or bleeding between the 2
delivery routes (2). However, there were signiﬁcantly fewer episodes
of new congestive heart failure in patients randomized to intra-
coronary abciximab bolus administration. The present analysis
reports 12 months of clinical results of the AIDA STEMI trial.
In brief, AIDA STEMI randomized 2,065 patients with acute
STEMI undergoing primary PCI to either intracoronary or intra-
venous abciximab bolus application with subsequent 12-h intra-
venous infusion. All patients received dual oral antiplatelet therapy
(aspirin and either clopidogrel or prasugrel). The primary endpoint
was a composite of all-cause death, reinfarction, or new congestive
heart failure at 90 days.
For the predeﬁned 12-month follow-up, the primary analysis was
performed for all patients who underwent randomization and had
follow-up information according to the intention-to-treat principle.
Predeﬁned subgroup analyses were performed for patient age, infarct
location, Killip class, post-procedural Thrombolysis In Myocardial
Infarction (TIMI) ﬂow, time from symptom onset to randomization,
and thrombectomy versus no thrombectomy. Exploratory post hocClinical Outcome at 1 Year
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Of the 2,065 patients enrolled, 1,876 patients underwent short-
term clinical follow-up at 90 days, whereas 189 patients were
excluded for reasons previously outlined (2). At 12 months, follow-up
was available for 1,846 patients (intracoronary group 925; intravenous
group 921; 98.4% follow-up rate relative to the 90-day landmark).
Baseline characteristics were well matched between groups. The
composite endpoint of death, reinfarction, and new congestive heart
failure was not signiﬁcantly different between patients assigned to
intracoronary versus intravenous abciximab bolus administration
(Table 1). A total of 51 patients (5.5%) had died in the intracoronary
comparedwith42 (4.6%) in the intravenousgroup (p¼0.39) (Table1).
At the 90-day landmark, more episodes of new congestive heart failure
in patients randomized to intravenous abciximab had been observed,
albeit at a p value of 0.04 only on the verge of statistical signiﬁcance (2).
At 12 months, the observed numerical difference in event rates proved
to be no longer signiﬁcantly different (p ¼ 0.07), supporting the
hypothesis that this ﬁnding is most likely due to chance. Consistent
with the overall cohort, predeﬁned as well as post hoc analyses revealed
no signiﬁcant differences in results across a wide range of subgroups
with regard to the combined endpoint of death, reinfarction, and
new congestive heart failure with the exception of female patients,
who seemed to beneﬁt from intracoronary bolus administration (odds
ratio: 0.55; 95% Conﬁdence Interval: 0.33 to 0.91).
The results of the present analysis suggest that in patients with
acute STEMI undergoing primary PCI and treated with dual oral
antiplatelet therapy, direct intracoronary compared with standard
intravenous bolus administration of abciximab does not result in
signiﬁcant differences with regard to hard clinical endpoints. This
might seem surprising given previous data that direct intracoronary
compared with intravenous abciximab bolus administration was
associated with a variety of beneﬁcial effects on surrogate markers
in patients with STEMI. Several considerations may serve toIntravenous
Abciximab
(n ¼ 921) p Value OR 95% CI
90 (9.8) 0.69 0.93 0.68–1.28
42 (4.6) 0.39 1.22 0.80–1.86
27 (2.9) 1.00 1.00 0.58–1.71
42 (4.6) 0.07 0.63 0.38–1.03
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1215explain these ﬁndings. First, despite being the largest trial studying
intracoronary abciximab administration to date, AIDA STEMI
might have been underpowered to detect small differences in
clinical endpoints. Second, AIDA STEMI used an “all-comers”
design. However, it is possible that intracoronary abciximab might
only be advantageous in selected patients such as those with large
thrombus burden, total occlusion, or reduced ﬂow. AIDA STEMI
subgroup analyses, however, do not support a selective beneﬁt of
intracoronary over intravenous bolus abciximab in high-risk
patients. Third, the magnitude of the short-lived local effect of
intracoronary abciximab might not be enough to produce changes
in clinically meaningful endpoints, especially in the era of routine
preloading with other potent antiplatelet agents. Fourth, in the
AIDA STEMI trial, abciximab was injected through the guiding
catheter after wiring of the infarct-related artery. Although easy to
implement in clinical practice, this way of delivery might be
suboptimal in selected patients because of inadequate thrombus
penetration of abciximab and possible retrograde washout into the
ascending aorta. Novel application systems such as dedicated
perfusion catheters might exert superior efﬁcacy by allowing high
local drug concentrations in both vessel lumen and wall at the site
of thrombus with prolonged focal dwelling times (3).
In conclusion, AIDA STEMI does not support a possible
clinical superiority of intracoronary bolus delivery. (Abciximab IV
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2012;307:1817–26.Letters to the EditorPost-Conditioning at the Ischemic
Region of the Heart to Prevent
Acute Kidney Injury in Patients
With Non–ST-Segment Elevation
Myocardial InfarctionWe read with great interest the paper by Deftereos et al. (1). The
authors proposed a reduced effect of ischemic post-conditioning at
the ischemic region of the heart on the incidence of acute kidney
injury in patients with non–ST-segment elevation myocardial
infarction (non–STEMI) undergoing percutaneous coronary inter-
vention (PCI).
Accumulating evidence has suggested that prolonged ischemic
duration before reperfusion is a critical determinant of infarct size
and determines the infarct size–limiting effect by post-conditioning
(2–5). Protective stimulus induced by postconditioning has been
conﬁrmed in patients with STEMI within 6 to 12 h of symptom
onset to balloon time (6,7). However, the stimulus effectiveness by
post-conditioning for a more prolonged time after symptom onset
has not been elucidated. On the other hand, the remote organ used
for effective conditioning usually does not have pre-existing
ischemic injury in clinical practice (8,9).
In this study, they enrolled patients with non-STEMI undergoing
PCI within 72 h after symptom onset. This is obviously a wide range
of ischemia duration. Moreover, the mean symptom onset to balloon
time was not reported in the post-conditioning and control groups.
The potential difference in this time between these 2 groups may
result in evident confounding bias. Therefore, we are interested
to know whether the onset time to PCI was evenly distributed
between the post-conditioning group and the control group.
